Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 15Terminated 10Active not recruiting 6Recruiting 3Withdrawn 2Unknown 1

Sponsor Class

OTHER 14INDUSTRY 3NIH 1NETWORK 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Solid Tumors 1Melanoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 166Injections 138Paclitaxel 118Gemcitabine 116Bevacizumab 113Cisplatin 105Docetaxel 80Cyclophosphamide 77Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 58Nivolumab 55fludarabine 54Cetuximab 52Leucovorin 51130-nm albumin-bound paclitaxel 48Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 33durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × encorafenib × Clear all
NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Pfizer

Phase 4 Recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

NCT04673955 2022-09-29

BERING-CRC

Pierre Fabre Pharma GmbH

Recruiting
500 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04045691 2021-01-19

BERING

Pierre Fabre Pharma GmbH

Recruiting
750 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡